Effects of LHRH-analogues on mitogenic signal transduction in cancer cells

被引:122
作者
Emons, G [1 ]
Müller, V [1 ]
Ortmann, O [1 ]
Schulz, KD [1 ]
机构
[1] Philipps Univ Marburg, Dept Obstet & Gynecol, D-35033 Marburg, Germany
关键词
D O I
10.1016/S0960-0760(97)00189-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of luteinizing hormone-releasing hormone (LHRH) and its receptors has been demonstrated in a number of human malignant tumors, including cancers of the breast, ovary, endometrium and prostate. These findings suggest the presence of an autocrine regulatory system based on LHRH. Recent studies in our laboratory have demonstrated that the function of LHRH produced by ovarian cancer cells is the inhibition of their proliferation. Dose-dependent antiproliferative effects of LHRH-agonists have been observed by several laboratories in cell lines derived from the above cancers. Interestingly, also LHRH-antagonists have marked antiproliferative activity in most of the ovarian, breast and endometrial cancer cell lines tested so far, indicating that the dichotomy of LHRH-agonists/LHRH-antagonists is not valid for the LHRH-system in cancer cells. In addition, our data suggest that the classical LHRH receptor signal transduction mechanisms known from the pituitary (phospholipase-C, protein kinase C, adenylyl cyclase) are not involved in the mediation of LHRH effects in cancer cells. Data obtained by several groups, including ours, rather suggest that LHRH analogs interfere with the signal transduction of growth-factor receptors and related oncogene products associated with tyrosine-kinase activity. The mechanism of action is probably an LHRH-induced activation of a phosphotyrosine phosphatase, counteracting the effects of receptor associated tyrosine kinase. In our hands, LHRH analogs virtually blocked the EGF-induced MAP-kinase activity of ovarian and endometrial cancer cells. The pharmacological exploitation of this mechanism might provide promising new therapies for these cancers. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 60 条
[1]   CHARACTERIZATION OF BINDING-SITES FOR A GNRH-AGONIST (BUSERELIN) IN HUMAN BREAST-CANCER BIOPSIES AND THEIR DISTRIBUTION IN RELATION TO TUMOR PARAMETERS [J].
BAUMANN, KH ;
KIESEL, L ;
KAUFMANN, M ;
BASTERT, G ;
RUNNEBAUM, B .
BREAST CANCER RESEARCH AND TREATMENT, 1993, 25 (01) :37-46
[2]   DIRECT INHIBITORY EFFECT OF A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST ON MCF-7 HUMAN-BREAST CANCER-CELLS [J].
BLANKENSTEIN, MA ;
HENKELMAN, MS ;
KLIJN, JGM .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (12) :1493-1499
[3]   HUMAN PLACENTAL GONADOTROPIN-RELEASING-HORMONE (GNRH) BINDING-SITES .3. CHANGES IN GNRH BINDING LEVELS WITH STAGE OF GESTATION [J].
BRAMLEY, TA ;
MCPHIE, CA ;
MENZIES, GS .
PLACENTA, 1994, 15 (07) :733-745
[4]  
CHATZAKI E, 1996, CANCER RES, V56, P2055
[5]   Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro [J].
Chegini, N ;
Rong, H ;
Dou, QC ;
Kipersztok, S ;
Williams, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3215-3221
[6]   EFFECT OF DECAPEPTYL(R) (A GNRH ANALOG) AND OF TRANSFORMING GROWTH-FACTOR-ALPHA (TGF-ALPHA), IN THE PRESENCE OF HEPARIN, ON THE SULFATASE ACTIVITY OF HUMAN BREAST-CANCER CELLS [J].
CHETRITE, G ;
BLUMBERGTICK, J ;
PASQUALINI, JR .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 52 (05) :451-457
[7]  
DONDI D, 1994, CANCER RES, V54, P4091
[8]   GONADOTROPIN-RELEASING-HORMONE (GNRH)-BINDING SITES IN HUMAN-BREAST CANCER CELL-LINES AND INHIBITORY EFFECTS OF GNRH ANTAGONISTS [J].
EIDNE, KA ;
FLANAGAN, CA ;
HARRIS, NS ;
MILLAR, RP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (03) :425-432
[9]   GONADOTROPIN-RELEASING HORMONE BINDING-SITES IN HUMAN EPITHELIAL OVARIAN CARCINOMATA [J].
EMONS, G ;
PAHWA, GS ;
BRACK, C ;
STURM, R ;
OBERHEUSER, F ;
KNUPPEN, R .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :215-221
[10]   HIGH-AFFINITY BINDING AND DIRECT ANTIPROLIFERATIVE EFFECTS OF LUTEINIZING-HORMONE-RELEASING HORMONE ANALOGS IN HUMAN ENDOMETRIAL CANCER CELL-LINES [J].
EMONS, G ;
SCHRODER, B ;
ORTMANN, O ;
WESTPHALEN, S ;
SCHULZ, KD ;
SCHALLY, AV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (06) :1458-1464